Aim: To check the safety and efficacy of boceprevir/telaprevir with peginterferon/ribavirin for hepatitis C virus (HCV) genotype 1 in the real-world settings.
Methods: This study was a non-randomized, observational, prospective, multicenter. This study involved 47 centers in Italy.